Stocks and Investing
Stocks and Investing
Wed, December 18, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, December 17, 2019
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Lewis Maintained (ABT) at Buy with Increased Target to $101 on, Dec 17th, 2019
David Lewis of Morgan Stanley, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $93 to $101 on, Dec 17th, 2019.
David has made no other calls on ABT in the last 4 months.
There are 2 other peers that have a rating on ABT. Out of the 2 peers that are also analyzing ABT, 0 agree with David's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with David
- Matt Miksic of "Credit Suisse" Maintained at Buy with Increased Target to $98 on, Thursday, October 17th, 2019
- Jayson Bedford of "Raymond James" Maintained at Buy with Decreased Target to $90 on, Monday, October 14th, 2019
Contributing Sources